scholarly journals N-terminal Pro-Brain Natriuretic Peptide, Adjuvant Laboratory Marker of Acute Phase of Kawasaki Disease in Emergency Department

2014 ◽  
Vol 1 (2) ◽  
pp. 96-101 ◽  
Author(s):  
Hyuksool Kwon
Keyword(s):  
Emergency Department ◽  
Kawasaki Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Acute Phase ◽  
Laboratory Marker

Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease

2002 ◽  
Vol 12 (2) ◽  
pp. 153-158 ◽  
Author(s):  
Takashi Kawamura ◽  
Masakuni Wago
Keyword(s):  
Kawasaki Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Acute Phase ◽  
Biochemical Marker ◽  
Cross Sectional ◽  
T Wave ◽  
Convalescent Phase ◽  
The Mean ◽  
St Segments

So as to determine the value of brain natriuretic peptide in the plasma as a biochemical marker for myocarditis of Kawasaki disease, we studied 69 patients. The blood samples, electrocardiograms and cross-sectional echocardiograms were obtained before the commencement of treatment and in the convalescent phase. Results: The mean concentration of brain natriuretic peptide in the plasma was 73.2 ± 107.7 (mean ± SD) pg/ml in the acute phase, and 7.9 ± 7.5 pg/ml in the convalescent phase. We checked the electrocardiograms to find abnormal Q waves, elevation or depression of the ST segments, change in the pattern of the QRS complexes, and flattening or inversion of the T wave, all believed to be markers of myocarditis in Kawasaki disease. Those in whom the concentrations were greater than 50 pg/ml in the acute phase showed abnormal electrocardiograms more frequently than did those in whom the values were less than 50 pg/ml (21/29 vs 3/40, p < 0.0001 odds ratio 32.4). Amplitudes of the T wave in standard limb leads were measured both in the acute and convalescent phases, and the differences calculated. We regarded the sum total of these differences as representing “flattening T wave”, and we named this variable as the total suppressed T wave voltage. We examined the correlation between the variable and the levels of brain natriuretic peptide in the plasma during the acute phase, demonstrating a significant correlation (r = 0.500, p < 0.0001). We conclude, therefore, that the concentration of brain natriuretic peptide measured in the plasma can be a useful biochemical marker for the myocarditis of Kawasaki disease. When the titer is over 50 pg/ml, the patient probably has an abnormal electrocardiogram and is most likely to have myocarditis.

N-terminal pro-brain natriuretic peptide can be an adjunctive diagnostic marker of hyper-acute phase of Kawasaki disease

2016 ◽  
Vol 175 (12) ◽  
pp. 1997-2003 ◽  
Author(s):  
Hyuksool Kwon ◽  
Jin Hee Lee ◽  
Jae Yun Jung ◽  
Young Ho Kwak ◽  
Do Kyun Kim ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Acute Phase ◽  
Diagnostic Marker

Factors affecting N-terminal pro-brain natriuretic peptide elevation in the acute phase of Kawasaki disease

2016 ◽  
Vol 58 (11) ◽  
pp. 1105-1111 ◽  
Author(s):  
Daisuke Yanagisawa ◽  
Mamoru Ayusawa ◽  
Masataka Kato ◽  
Hirofumi Watanabe ◽  
Akiko Komori ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Acute Phase ◽  
Factors Affecting

scholarly journals Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3

2018 ◽  
Vol 47 (1) ◽  
pp. 159-172 ◽  
Author(s):  
Alexandra Stoica ◽  
Victoriţa Şorodoc ◽  
Cătălina Lionte ◽  
Irina M. Jaba ◽  
Irina Costache ◽  
...  
Keyword(s):  
Emergency Department ◽  
High Risk ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Clinical Manifestations ◽  
Diagnostic Value ◽  
Left Ventricular ◽  
Diagnostic Methods ◽  
Left Ventricular Ejection ◽  
Galectin 3

Objective This study was performed to determine whether a dual-biomarker approach using N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and galectin-3 optimizes the diagnosis and risk stratification of acute cardiac dyspnea. Atypical clinical manifestations and overlapping pathologies require objective and effective diagnostic methods to avoid treatment delays. Methods This prospective observational study included 208 patients who presented to the emergency department for acute dyspnea. NT-proBNP and galectin-3 were measured upon admission. The patients were divided into two groups according to the etiology of their clinical manifestations: cardiac and non-cardiac dyspnea. The patients’ New York Heart Association functional class, left ventricular ejection fraction, and discharge status were assessed. Results Diagnostic criteria for acute heart failure were fulfilled in 61.1% of the patients. NT-proBNP and galectin-3 were strongly and significantly correlated. Receiver operating characteristic analysis revealed similar areas under the curve for both markers in the entire group of patients as well as in the high-risk subsets of patients. Conclusions The diagnostic performance of NT-proBNP and galectin-3 is comparable for both the total population and high-risk subsets. Galectin-3 adds diagnostic value to the conventional NT-proBNP in patients with acute cardiac dyspnea, and its utility is of major interest in uncertain clinical situations.

Sign in / Sign up

Export Citation Format

Share Document